Menu
Search
|

Menu

Close
X

Nightstar Therapeutics PLC NITE.OQ (NASDAQ Stock Exchange Global Select Market)

15.26 USD
+0.12 (+0.79%)
As of 9:35 AM EST
chart
Previous Close 15.14
Open 15.24
Volume 2,722
3m Avg Volume 40,351
Today’s High 15.26
Today’s Low 15.16
52 Week High 28.38
52 Week Low 9.62
Shares Outstanding (mil) 32.88
Market Capitalization (mil) 428.15
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
EPS (USD)
FY18
-0.804
FY17
-0.297
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.37
Price to Sales (TTM)
vs sector
--
20.58
Price to Book (MRQ)
vs sector
3.77
4.23
Price to Cash Flow (TTM)
vs sector
--
21.21
Total Debt to Equity (MRQ)
vs sector
0.00
13.84
LT Debt to Equity (MRQ)
vs sector
0.00
9.93
Return on Investment (TTM)
vs sector
--
13.58
Return on Equity (TTM)
vs sector
--
15.11

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

9-10 Midford Place
LONDON   MA   W1T 5BJ

Phone: +4420.76112077

Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases. The Company’s lead product candidate, NSR-REP1, for the treatment of choroideremia, or CHM, is entering Phase III clinical development. The Company is also conducting a Phase I/II clinical trial with its second product candidate, NSR-RPGR, for the treatment of X-linked retinitis pigmentosa, or XLRP. The Company’s third product candidate, NSR-BEST1, is in preclinical development for the treatment of Best vitelliform macular dystrophy, or Best disease.

SPONSORED STORIES